| dc.description.abstract | Background: Pentraxin-3 (PTX3) is a marker of inflammation that can be used
independently to predict the cardiovascular events, progression, and mortality of
acute coronary syndrome (ACS). ACS with diabetes mellitus (DM) is a specific
population with even higher risk of outcome and mortality compare to non-DM ACS
patients. The aim of this study is to evaluate the difference of PTX3 in ACS patients
with or without type 2 DM.
Methods: This study is an analytic-cross sectional study at cardiovascular emergency
department H. Adam Malik General Hospital Medan, Indonesia (December 2022 –
May 2023). We included 60 ACS patients (30 with DM and 30 without DM) that met
our inclusion and exclusion criterias. Blood sample was 6 ml vein blood. PTX3 was
measured by ELISA method (Chemwell analyzer). Statistical analysis was evaluated
by SPSS ver. 25
Results: The mean age in this study was 58.9 ± 9.5 year with male proportion of
71,7%. Proportion of hypertension and smoking were 43.3% and 61.7%, respectively.
Glucose ad random in ACS with DM was 235 mg/dL and in ACS without DM was
128.5 mg/dL (p < 0.001). PTX3 in ACS with DM and without DM differe
significantly (8.79 ng/mL [5.01 – 17.60] vs 6.49 ng/mL [3.67 – 13.72]; p < 0.001).
PTX3 can be used as a marker to predict ACS event in DM and without DM with
PTX3 cut-off 7.92 ng/mL (AUC 77,4%; p < 0,001; sensitivity 73,3%; spesifisity
83,3%).
Conclusion: PTX3 in ACS with and without type 2 DM differe significantly. PTX3
can be used as a marker to predict the ACS event in type 2 DM and without type 2
DM. | en_US |
